Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model
about
Mucormycosis, pseudallescheriasis, and other uncommon mold infectionsFungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lysDiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsCharacterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.Aerosolized liposomal Amphotericin B: a potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients.Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosisLiposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.Conventional liposome performance and evaluation: lessons from the development of Vescan.Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem celTissue penetration of antifungal agents.Efficacy and safety of current drug therapies for invasive aspergillosis.Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus.Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens.Aerosolized Delivery of Antifungal AgentsProteomic and transcriptomic analysis of Aspergillus fumigatus on exposure to amphotericin B.Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice.Amphotericin B concentrations in healthy mallard ducks (Anas platyrhynchos) following a single intratracheal dose of liposomal amphotericin B using an atomizer.Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine.Efficacy of liposomal amphotericin B for prophylaxis of acute or reactivation models of invasive pulmonary aspergillosis.Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.
P2860
Q24603297-49FD4CD9-EEFC-4334-B87B-7EF60DC2716BQ26740363-44259779-9434-42B6-B117-076882DF5929Q31161843-C20CD6AE-218D-4693-B081-CE73C1D5BC2AQ33753500-85FC5409-C635-4DA3-B11B-16F2193410D1Q34108585-30A7920F-E4C6-4589-B689-662A1CF25042Q34763371-2C7EE4ED-C10D-41A2-BFA2-70861EF97A57Q34811537-508B6B9B-0F0D-4343-9743-BDBB3B0F9338Q35168703-5578A68E-3EDD-4AD1-91A7-CAD994B91D5AQ35758926-CFE9EAE6-F0B2-48B1-9B6C-DAA9BD9C6BA7Q36422661-1D6A1B06-FC9B-45BA-815A-26F763B75E3DQ36757621-ED89B898-FD07-4B37-9BF2-B9A8A7B1E751Q36868273-04A169FD-5189-4383-BDA5-B3B3BAECE226Q36949553-8ECE5A66-258D-4055-B4D9-64158C9BC6DDQ37008683-4795BD70-5CB3-40CA-B4E8-314B5598DFDAQ37333175-045E737A-8DB4-4C24-B49D-B0546564D23AQ37544911-43416BBD-176E-44AD-B564-D7EF75810868Q37944001-6E2E5975-66B1-4380-9B24-F49AE9BE68FBQ39661366-BE07F128-6302-4FC1-B8E2-5634A9A7B745Q40222438-A1FA6D9F-B561-41C6-99A5-1E2240A07ABEQ40522508-1D6D52D5-C2C4-4DC7-85C2-8EC71E7BFFE5Q41389247-09217A04-AB2B-4A75-B807-8163E1FB43F9Q41570433-04288DA2-7DEB-4C19-8F17-5F998698828AQ41989595-FEFC6138-6F2E-4025-830E-86DD6EB40080Q42227869-CC234051-267B-4840-BA5E-BE907E0D420CQ43102684-00CC185B-3150-4247-871B-DE7E47F67494Q45353811-F49D2408-7528-442B-8CE1-A1DFD3A8736FQ46284853-358F267E-603C-4E3D-82EE-5EA105E70437Q46808821-AC12A383-9ECD-4853-A106-95CF6E7929E1
P2860
Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Comparative efficacies, toxici ...... pulmonary aspergillosis model
@ast
Comparative efficacies, toxici ...... pulmonary aspergillosis model
@en
Comparative efficacies, toxici ...... pulmonary aspergillosis model
@nl
type
label
Comparative efficacies, toxici ...... pulmonary aspergillosis model
@ast
Comparative efficacies, toxici ...... pulmonary aspergillosis model
@en
Comparative efficacies, toxici ...... pulmonary aspergillosis model
@nl
prefLabel
Comparative efficacies, toxici ...... pulmonary aspergillosis model
@ast
Comparative efficacies, toxici ...... pulmonary aspergillosis model
@en
Comparative efficacies, toxici ...... pulmonary aspergillosis model
@nl
P2093
P2860
P356
P1476
Comparative efficacies, toxici ...... pulmonary aspergillosis model
@en
P2093
Gerard M Jensen
Jill P Adler-Moore
Jon A Olson
Julie Schwartz
Richard T Proffitt
P2860
P304
P356
10.1128/AAC.00315-06
P407
P577
2006-06-01T00:00:00Z